Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Gastroenterology and Hepatology: Bridging Basic Science, Clinical Insights,...
share announcement

Advances in Gastroenterology and Hepatology: Bridging Basic Science, Clinical Insights, and Translational Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 137

Special Issue Editors

Dr. Abdulrahman Ismaiel

E-Mail Website
Guest Editor
2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
Interests: chronic liver disease; MASLD; liver cirrhosis; IBS; disorders of gut–brain interaction; non-invasive markers
Dr. Ștefan Lucian Popa

E-Mail Website
Guest Editor
2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
Interests: disorders of gut–brain interaction; artificial intelligence; esophageal motility disorders; high-resolution esophageal ma-nometry

Special Issue Information

Dear Colleagues,

Gastroenterology and hepatology are dynamic fields that integrate basic science, clinical innovation, and translational research to enhance patient outcomes. The growing burden of gastrointestinal and liver diseases worldwide underscores the urgency of advancing diagnostic approaches, therapeutic strategies, and preventive measures.

This Special Issue aims to provide a comprehensive platform for researchers and clinicians to showcase cutting-edge developments in gastroenterology and hepatology. We welcome submissions that explore innovative research, clinical trials, and multidisciplinary approaches to the following topics:

  • Emerging biomarkers for gastrointestinal and liver diseases.
  • Advances in endoscopic and imaging techniques.
  • Novel therapeutic strategies for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
  • Hepatocellular carcinoma: Early detection and personalized treatment.
  • Gut microbiota and its implications in systemic diseases.
  • Advances in the management of liver fibrosis and cirrhosis.
  • Translational approaches for autoimmune and metabolic liver disorders.
  • Integration of artificial intelligence in diagnostic and therapeutic tools in gastroenterology.

We encourage submissions of original research articles, reviews, and perspectives that foster collaboration across disciplines. By featuring contributions that span basic science, translational studies, and clinical practice, this Special Issue seeks to bridge gaps in knowledge and promote innovative solutions to pressing challenges in gastroenterology and hepatology.

Dr. Abdulrahman Ismaiel
Dr. Ștefan Lucian Popa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatology
  • gastroenterology
  • IBD
  • IBS
  • MASLD
  • liver cirrhosis
  • artificial intelligence
  • disorders of gut–brain interaction
  • cancer
  • gut microbiota
  • diagnosis
  • management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 580 KiB  
Article
The Impact of Non-Invasive Scores and Hemogram-Derived Ratios in Differentiating Chronic Liver Disease from Cirrhosis
by Abdulrahman Ismaiel, Evrard Katell, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Cristina Sorina Catana, Dan L. Dumitrascu and Teodora Surdea-Blaga
J. Clin. Med. 2025, 14(9), 3072; https://doi.org/10.3390/jcm14093072 - 29 Apr 2025
Abstract
Background: Chronic liver disease (CLD) is a major global health concern, contributing significantly to morbidity and mortality. Cirrhosis and liver cancer are the leading causes of liver-related deaths, with various etiological factors, such as metabolic disorders and alcohol-related and viral hepatitis, driving its [...] Read more.
Background: Chronic liver disease (CLD) is a major global health concern, contributing significantly to morbidity and mortality. Cirrhosis and liver cancer are the leading causes of liver-related deaths, with various etiological factors, such as metabolic disorders and alcohol-related and viral hepatitis, driving its global prevalence. Non-invasive biomarkers and scoring systems have emerged as key tools for assessing liver disease severity and differentiating CLD from cirrhosis. This study evaluates biomarkers and non-invasive scores and their utility in distinguishing CLD from cirrhosis. Methods: This retrospective observational study included 250 adult patients hospitalized between January 2021 and December 2023 at Cluj County Emergency Clinical Hospital, Romania. Patients were diagnosed with either cirrhosis or CLD of viral, autoimmune, or primary biliary cholangitis (PBC) etiology. Non-invasive biomarkers, scores, and various hemogram-derived ratios were evaluated. Statistical analysis involved descriptive statistics, comparative tests, and receiver operating characteristic (ROC) curve analysis. Results: Among the 250 patients, 137 had liver cirrhosis (54.8%) and 113 had CLD without cirrhosis (45.2%). Significant differences were observed in laboratory parameters, with cirrhosis patients showing lower hemoglobin, platelet count, and albumin levels alongside higher liver enzymes and INR values. Non-invasive scores such as APRI, FIB-4, and NFS demonstrated higher values in the cirrhosis group, indicating more advanced liver damage. Hemogram-derived ratios, particularly the neutrophil-to-lymphocyte ratio (NLR), were higher in cirrhosis patients. ROC analysis revealed that the Lok index had the highest discriminatory power (AUC 0.89), followed by the King score (AUC 0.864) and the Fibrosis index (AUC 0.856), which effectively distinguished cirrhosis from CLD. Conclusions: This study underscores the utility of non-invasive biomarkers and scoring systems in differentiating CLD from cirrhosis. The Lok index, King score, and Fibrosis index demonstrated excellent diagnostic accuracy, while hemogram-derived ratios, such as NLR, offer insights into systemic inflammation associated with liver disease progression. These findings support the integration of non-invasive markers into clinical practice for improved risk stratification and management of liver diseases. Full article
(This article belongs to the Special Issue Advances in Gastroenterology and Hepatology: Bridging Basic Science, Clinical Insights, and Translational Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop